Fluence Collaboration With Dutch Propagator WPK Creates Immediate Improvements in Plant Quality and Uniformity
14.9.2022 15:30:00 EEST | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its collaboration with Westlandse Plantenkwekerij (WPK), a large Dutch propagator specializing in young plant cultivation for greenhouse horticulture in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220914005286/en/
One of the larger propagators in the Netherlands, Westlandse Plantenkwekerij, implemented a hybrid lighting approach using Fluence’s VYPR fixtures, resulting in increased quality and control over environmental factors. (Photo: Business Wire)
Originally founded in the 1930s by Arie van der Arend, WPK is a multi-generational family business now run by van der Arend’s descendants, Erik and Eviek. As a propagator, WPK oversees the seed-to-plant process for vegetable and tray plants for growers throughout Europe. The company’s scientific approach to cultivation has led to decades of success, ultimately driving WPK to enlist Fluence’s help to install research-backed LED lighting at their ’s-Gravenzande facility, jointly owned with Plantenkwekerij P. van Geest, for the very first time.
WPK introduced Fluence’s VYPR Series top lights alongside existing legacy high-pressure sodium (HPS) fixtures to harness the unique control a hybrid lighting approach offers for optimizing environmental factors—including controlling ambient heat. The hybrid lighting model at WPK’s facilities has led to better management of seasonal growing conditions and notable energy savings.
“After installing Fluence’s LED lighting solutions, we learned that young plants thrive in LED-lit environments,” said Erik van der Arend, managing director of WPK. “This has allowed us the flexibility to grow a wide range of crops in the same environment and under the same lighting conditions, decreasing hassle and improving our energy costs. The transition to Fluence has helped improve plant quality and speed of development, ensuring our customers get a uniform product that is consistently excellent.”
In collaboration with Fluence’s horticultural lighting experts, WPK fine-tuned the LEDs’ spectra to optimize operational costs while maintaining superior quality for the grower’s tomato, cucumber, pepper and flower crops. Early results show that WPK is realizing an estimated electricity savings between 40 and 50% by using two-thirds Fluence LED fixtures and one-third HPS in the greenhouse. Additionally, WPK increased total light levels by 30% due to the overall efficiency of LED technology. The post-installation harvests produced more compact, generative and vigorous plants that were darker or richer in color.
“The interesting thing about Fluence’s lighting technology is the right degree of cooling—the luminaire doesn’t get very hot,” van der Arend added. “Moreover, the spectrum is widely applicable.”
“When you work with Fluence, you’re not just buying a standalone LED light. You’re tapping into a network of leading lighting and horticultural experts who can help you create the right conditions to optimize your cultivation environment,” said Timo Bongartz, general manager of Europe, Middle East and Africa at Fluence. “That’s why we love working with propagators like WPK who share our passion for developing innovative lighting and environmental control strategies.”
For more information about the collaboration, visit here.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
About WPK
Westlandse Plantenkwekerij (WPK) is a specialist in vegetable cultivation for professional greenhouse horticulture in Europe. WPK was established in the 1930s and currently has four cultivation facilities: two in 's-Gravenzande (South-Holland) and two in Made (North-Brabant). WPK makes the world a little greener with the cultivation of vegetable plants (such as tomato, pepper and cucumber), tray plants and potted flowering plants.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005286/en/
Contact information
Media Contact:
For EMEA,
Silvia Nagyova
silvia.nagyova@fluence-led.com
+49 (89) 6213-3939
For North America,
Emma Chase
pr@fluencebioengineering.com
512-917-4319
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
